QUEBEC CITY, Feb. 28, 2017 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is
pleased to announce that it has received final approval for the
listing of the Corporation's common shares (the "Common Shares") on
the Toronto Stock Exchange ("TSX").
The Common Shares will commence trading on the TSX effective as
of the open of the market on March 1, 2017. Upon listing
on the TSX, the Common Shares will continue to trade under the
symbol "OPS". In conjunction with listing on the TSX, the
Common Shares will be voluntarily delisted from the TSX
Venture Exchange prior to the commencement of trading on March
1, 2017.
"This is a significant achievement for Opsens," said
Louis Laflamme, President and Chief
Executive Officer of Opsens. "The TSX is Canada's most significant stock exchange and
this move will provide us with greater visibility in the
marketplace and access to a broader and more diverse range of
international and institutional investors. This move will also help
Opsens develop a stronger profile in the investment community, as
our penetration grows, on a global scale, in the field of
interventional cardiology," Mr. Laflamme added.
Opsens aims to become a key player in the guidewire FFR market
with the OptoWire, a nitinol-based, fiber optic guidewire. The
OptoWire provides intra-coronary blood pressure measurements with
unique, patented optical pressure guidewire technologies. It is
immune to undesired effects related to blood contact, and allows
easy and reliable connectivity that leads to reliable FFR
measurements in extended conditions of usage. The OptoWire is also
designed to provide cardiologists with a guidewire that provides
optimal performance to navigate coronary arteries and cross
blockages with ease and safety. Based on industry sources, the FFR
market represented more than US$300
million in sales in 2014 and is expected to reach
US$1 billion in the medium-term.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Company develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications such as the monitoring of oil wells and other
demanding industrial applications.
Forward-looking statements contained in this press release
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of
Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE OPSENS INC.